VYNT News and Press, Vyant Bio Inc. From 03/30/22

Vyant Bio, Inc. (VYNT) Q4 2021 Earnings Conference Call March 30, 2022 8:30 AM ET Company Participants Jay Roberts - Chief Executive Officer Andrew LaFrence - Chief Financial Officer Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Presentation...

Gainers: Adagio Therapeutics (ADGI) +48%. Vyant Bio (VYNT) +23%. Vir Biotechnology (VIR) +19%. Sonoma Pharmaceuticals (SNOA) +15%. Syros Pharmaceuticals (SYRS) +15%. Losers: Revelation Biosciences (REVB) -40%. UpHealth (UPH) -29%. The Valens (VLNS)...

Buying Penny Stocks Today? Here’s What You Need to Know Buying penny stocks in 2022 is not for the faint of heart. With so much going on in the stock market, trading penny stocks and blue chips in the last few weeks has been extremely volatile, to say the least. And although ...

Adagio Therapeutics (ADGI) +64% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2. Vyant Bio (VYNT) +29% on FY results. Sonoma Pharmaceuticals (SNOA) +24% launches new urinary tract infection product through distributors in New Zealand, Australia and Sou...

Vyant Bio press release (NASDAQ:VYNT): FY GAAP EPS of -$1.81. Revenue of $1.15M (+32.2% Y/Y). Cash and cash equivalents totaled $20.6 million as of December 31, 2021 Shares +28% PM. For further details see: Vyant Bio GAAP EPS of -$1.81, revenue of $1.15M

Highlights Focused as a pure-play drug discovery and development biotechnology company Primary work on the discovery of small molecule therapeutics to treat neurodevelopmental and neurodegenerative diseases for Rett Syndrome (“Rett”), CDKL5 Deficiency Disorder ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine, investor! It’s time to go over the biggest pre-market stock movers in our breakdown for Wednesday! Source: Shutterstock Most of the stock movement this morning comes from earnings reports but ...

The shares of micro-cap biotech, Vyant Bio (VYNT +16.4%) have added ~17% in the post-market Tuesday after announcing a collaboration agreement with Luxembourg-based OrganoTherapeutics to discover drugs for the treatment of Parkinson’s Disease. A spin-off from the Luxembourg Centre for ...

Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative dis...

CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’...